BioMarin Pharmaceuticals Inc

BMRN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
BMRN Income Statement
BMRN Balance Sheet
BMRN Cash Flow
Congress Trading

Recent trades of BMRN by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Mar. 06, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Oct. 18, 2021
Gilbert Ray Cisneros, Jr. House / D Purchase $15,001 - $50,000 Dec. 30, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 Oct. 16, 2020
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep. 15, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 16, 2019
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec. 11, 2019
Alan S. Lowenthal House / D Sale $506.27 Aug. 15, 2019
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Aug. 15, 2019
Alan S. Lowenthal House / D Sale $217.10 Aug. 14, 2019
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Aug. 14, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Mar. 25, 2019
Alan S. Lowenthal House / D Purchase $903.36 May. 29, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Apr. 27, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Apr. 26, 2018
Lamar Smith House / R Sale $1,001 - $15,000 Feb. 12, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Jan. 18, 2018
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Jan. 17, 2018
K. Michael Conaway House / R Sale $1,001 - $15,000 Sep. 12, 2016
Thomas MacArthur House / R Sale $1,001 - $15,000 Jan. 27, 2015
Lamar Smith House / R Purchase $1,001 - $15,000 Nov. 14, 2014
BMRN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
BMRN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BMRN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BMRN's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $240,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
  • $180,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $410,000 Apr 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $470,000 Jan 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $220,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $210,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $420,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $170,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $220,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $560,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $270,000 Jan 20, 2022 Issue: Immigration Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $190,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $190,000 Jul 20, 2021 Issue: Health Issues Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code
  • $390,000 Apr 20, 2021 Issue: Immigration Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $510,000 Jan 21, 2021 Issue: Immigration Medicare/Medicaid Health Issues
  • $230,000 Oct 20, 2020 Issue: Immigration Medicare/Medicaid Health Issues
  • $250,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
  • $370,000 Apr 20, 2020 Issue: Medicare/Medicaid Health Issues
  • $390,000 Jan 21, 2020 Issue: Immigration Health Issues Medicare/Medicaid
  • $160,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Immigration
  • $110,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $410,000 Apr 22, 2019 Issue: Health Issues Medicare/Medicaid
  • $340,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $120,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid
  • $110,000 Jul 20, 2018 Issue: Medicare/Medicaid Health Issues
  • $250,000 Apr 20, 2018 Issue: Health Issues
  • $290,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $150,000 Oct 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $350,000 Jul 20, 2017 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $280,000 Jul 20, 2017 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $210,000 Jan 23, 2017 Issue: Health Issues
  • $120,000 Oct 20, 2016 Issue: Medicare/Medicaid Health Issues
  • $90,000 Jul 20, 2016 Issue: Health Issues
  • $80,000 Apr 20, 2016 Issue: Health Issues
  • $60,000 Jan 20, 2016 Issue: Health Issues
  • $60,000 Oct 20, 2015 Issue: Health Issues
  • $50,000 Jul 20, 2015 Issue: Health Issues Trade (domestic/foreign)
  • $60,000 Apr 20, 2015 Issue: Taxation/Internal Revenue Code Health Issues
  • $120,000 Jan 20, 2015 Issue: Health Issues Taxation/Internal Revenue Code
  • $50,000 Oct 21, 2014 Issue: Taxation/Internal Revenue Code Health Issues
  • $60,000 Jul 21, 2014 Issue: Taxation/Internal Revenue Code Health Issues
  • $60,000 Apr 21, 2014 Issue: Health Issues
  • $30,000 Jan 21, 2014 Issue: Health Issues
  • $30,000 Oct 21, 2013 Issue: Taxation/Internal Revenue Code Pharmacy
  • $10,000 Jul 22, 2013 Issue: Taxation/Internal Revenue Code Health Issues
  • $80,000 Oct 20, 2009 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Sep. 03, 2024
  • Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects Mar. 05, 2024
  • Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Feb. 27, 2024
  • Patent Title: Liver targeting adeno-associated viral vectors Nov. 21, 2023
  • Patent Title: Methods of treating phenylketonuria Aug. 29, 2023
  • Patent Title: Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same Jul. 04, 2023
  • Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Feb. 28, 2023
  • Patent Title: Adeno-associated virus capsid proteins Feb. 21, 2023
  • Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof Nov. 22, 2022
  • Patent Title: Adeno-associated virus factor viii vectors Aug. 09, 2022
  • Patent Title: Glycolate oxidase inhibitors for the treatment of disease Jul. 12, 2022
  • Patent Title: N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors Jun. 14, 2022
  • Patent Title: Lysosomal targeting peptides and uses thereof Jun. 07, 2022
  • Patent Title: Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof May. 31, 2022
  • Patent Title: Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes Mar. 01, 2022
  • Patent Title: Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof Feb. 22, 2022
  • Patent Title: Tpp-1 formulations and methods for treating cln2 disease Jan. 25, 2022
  • Patent Title: Use of c-type natriuretic peptide variants to treat osteoarthritis Dec. 21, 2021
  • Patent Title: Delivery of therapeutic compounds to the brain and other tissues Jun. 22, 2021
  • Patent Title: Histone deacetylase inhibitors Apr. 20, 2021
  • Patent Title: Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof Mar. 02, 2021
  • Patent Title: Histone deacetylase inhibitors Dec. 01, 2020
  • Patent Title: Variants of c-type natriuretic peptide Oct. 20, 2020
  • Patent Title: Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Oct. 06, 2020
  • Patent Title: Tpp-1 formulations and methods for treating cln2 disease Sep. 01, 2020
  • Patent Title: Detection of oligosaccharides Jun. 16, 2020
  • Patent Title: Methods of diagnosing mucopolysaccharidosis (mps) i and methods of monitoring treatment of mps by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Jun. 09, 2020
  • Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia May. 12, 2020
  • Patent Title: Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof Feb. 18, 2020
  • Patent Title: Histone deacetylase inhibitors Jan. 07, 2020
  • Patent Title: Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same Dec. 24, 2019
  • Patent Title: Adeno-associated virus factor viii vectors Nov. 05, 2019
  • Patent Title: Hdac inhibitors Oct. 01, 2019
  • Patent Title: Histone deacetylase inhibitors Jun. 04, 2019
  • Patent Title: Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins May. 28, 2019
  • Patent Title: Histone deacetylase inhibitors May. 28, 2019
  • Patent Title: Targeted therapeutic proteins May. 28, 2019
  • Patent Title: Histone deacetylase inhibitors May. 07, 2019
  • Patent Title: Tpp-1 formulations and methods for treating cln2 disease May. 07, 2019
  • Patent Title: Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Apr. 16, 2019
  • Patent Title: N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors Mar. 26, 2019
  • Patent Title: Glucosylceramide synthase inhibitors for the treatment of diseases Mar. 12, 2019
  • Patent Title: Glucosylceramide synthase inhibitors for the treatment of diseases Mar. 12, 2019
  • Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof Mar. 05, 2019
  • Patent Title: Histone deacetylase inhibitors Aug. 28, 2018
  • Patent Title: Hdac inhibitors Jul. 24, 2018
  • Patent Title: Methods and compositions for the treatment of metabolic disorders Jun. 12, 2018
  • Patent Title: Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (mps) vi and iva Mar. 13, 2018
  • Patent Title: Histone deacetylase inhibitors Mar. 06, 2018
  • Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Mar. 06, 2018
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of BMRN in WallStreetBets Daily Discussion

BMRN News

Recent insights relating to BMRN

CNBC Recommendations

Recent picks made for BMRN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BMRN

BMRN Top Shareholders
Shareholder
Shares Held
BMRN Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BMRN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BMRN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top